You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Booster-Free Dosing

Go to Top Close

DOLUTEGRAVIR ▼ – sustained efficacy and a high barrier to resistance without the need to boost

Dolutegravir – a core agent that provides confidence and convenience

Are we entering a booster-free era?

Expert discussion with Prof. José Gatell and Dr. Marta Boffito

*In the presence of integrase resistance, dolutegravir should be taken twice daily, preferably with food. Triumeq is a fixed-dose tablet and should not be prescribed for patients requiring dose adjustments. Please see the Tivicay and Triumeq Summary of Product Characteristics for further details. [5],[6]

Triumeq is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.[5]

For further information, please see the Summary of Product Characteristics.

References:

  1. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naïve patients: week 96 and week 144 results from the SINGLE randomised clinical trial. J Acquir Immune Defic Syndr. 2015;70:515-519.
  2. Molina J-M, Clotet B, van Lunzen J, et al; on behalf of the FLAMINGO Study Team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127-e136.
  3. Orrell C, Hagins D, Belonosova E, et al. Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA Study). Presented at: Annual International AIDS Conference 2016; July 18-22, 2016. Durban, South Africa.
  4. Raffi F, Jaeger H, Quiros-Roldan E, et al;  on behalf of the SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2): 96 week results from a randomised, double-bild, non-inferiority trial. Lancet Infect Dis. 2013:13(11):927-935
  5. TRIUMEQ Summary of Product Characteristics.
  6. TIVICAY Summary of Product Characteristics.
  7. University of Liverpool. Drug interactions chart July 2016. www.hiv-druginteractions.org. Accessed July 15, 2016.
  8. Tenofovir/emtricitabine/elvitegravir/cobicistat Summary of Product Characteristics. Available from: www.medicines.ie, accessed Dec 2016.
  9. Raltegravir Summary of Product Characteristics. Available from: www.medicines.ie , accessed Dec 2016.
  10. Tenofovir/efavirenz/emtricitabine Summary of Product Characteristics. Available from: www.medicines.ie, accessed Dec 2016.
  11. Tenofovir/emtricitabine/rilpivirine Summary of Product Characteristics. Available from: www.medicines.ie, accessed Dec 2016.
  12. Atazanavir Summary of Product Characteristics. Available from: www.medicines.ie , accessed Dec 2016.
  13. Darunavir / ritonavir Summary of Product Characteristics. Available from: www.medicines.ie, accessed Dec 2016.
  14. Darunavir/cobicistat Summary of Product Characteristics. Available from: www.medicines.ie, accessed Dec 2016.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Tivicay & Triumeq is registered trademark of the GlaxoSmithKline Group of Companies